Weekly Lung Cancer News Update

Week Ending July 21, 2008

ASA404 Programme to Expand with New Pivotal Trial in Lung Cancer
“Antisoma plc today announced that its Tumour-Vascular Disrupting Agent, ASA404, will enter a second pivotal phase III trial this year. The ATTRACT-2 (Anti-vascular Targeted Therapy: Researching ASA404 in Cancer Treatment-2) trial will be conducted by Antisoma's partner, Novartis, and will evaluate ASA404 as a second-line treatment for non-small cell lung cancer (NSCLC).”

BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept Clinical Trial
“BioNumerik Pharmaceuticals, Inc. today announced that patients with adenocarcinoma (the most frequently occurring form of lung cancer) participating in a Phase II clinical trial of Tavocept(TM) showed a survival increase of approximately 198 days (6.5 months). The trial observations included an approximate 40% reduction in mortality for adenocarcinoma patients receiving Tavocept.”

KSU Researchers Discover Lung Cancer Biomarker
ARAB NEWS: RIYADH: “King Saud University yesterday announced the discovery of a new lung cancer biomarker by a team of scientists and students led by V. Masilamani of the College of Science.”

Magnolia Compound Hits Elusive Target in Cancer Cells
ScienceDaily — “A natural compound from magnolia cones blocks a pathway for cancer growth that was previously considered "undruggable," researchers have found.”

Cancer Survivors Help Each Other to Live Stronger
“Radine Cox's story is hers alone, but in a way, the 58-year-old Decatur woman's tale echoes the experiences of countless others.”

Lung Cancer Benefit at Palaia Vineyards
“Palaia Vineyards is hosting a Neil Young Tribute Festival to benefit Joan’s Legacy against Lung Cancer on July 26 and 27 beginning at noon.”